购物车
- 全部删除
- 您的购物车当前为空
Spebrutinib (LMK-435) 是一种共价的、高效的、选择性的、具有口服活性的Btk 抑制剂 (IC50:0.5 nM)。
Spebrutinib (LMK-435) 是一种共价的、高效的、选择性的、具有口服活性的Btk 抑制剂 (IC50:0.5 nM)。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | ¥ 498 | 现货 | |
10 mg | ¥ 747 | 现货 | |
50 mg | ¥ 2,161 | 现货 | |
100 mg | ¥ 3,717 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 548 | 现货 |
产品描述 | Spebrutinib (LMK-435) is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. |
靶点活性 | BTK:<0.5 nM |
体外活性 | 口服3-30 mg/kg AVL-292抑制胶原蛋白诱导的小鼠关节炎模型中的炎症临床症状,包括关节和爪肿胀以及感染爪的可见发红的减少. |
体内活性 | AVL-292通过抑制BTK的活性,进一步抑制B细胞的增殖,EC50为3 nM。AVL-29对在Ramos细胞中的BTK产生抑制作用,EC50为8 nM,具有剂量依赖性,并且抑制了下游的BCR通路。 |
激酶实验 | Procedures for BTK OMNIA Assay: The Omnia continuous read assay is performed essentially as described by the vendor. The assay conditions are: 40 μM ATP (1X KMATP), 10 μM Y5-Sox, and 10 nM BTK enzyme. Briefly, a substrate mix containing 1.13X ATP and the Y5 Sox substrate is first prepared in 1X Omnia Kinase Reaction Buffer (KRB) consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM?β-glycerophosphate, 5% glycerol, and 0.2 mM DTT. For IC50 measurements, 5 μL of enzyme are incubated with serially diluted (3-fold) compounds prepared in 50% DMSO in a Corning (#3574) 384-well, white, non-binding surface microtiter plate at 25°C for 30 min. Kinase reactions are started with the addition of 45 μL of the ATP/Y5 substrate mix and monitored at λex360/λem485 in a Synergy 4 plate reader for 60 minutes. Progress curves from each well are examined for linear reaction kinetics and fit statistics. Initial velocity from each reaction is determined from the slope of a plot of relative fluorescence units versus time and then plotted against inhibitor concentration to estimate IC50 using the Response, Variable Slope model in GraphPad Prism from GraphPad Software. |
细胞实验 | A suspension of resting purified na?ve human B cells isolated by negative selection in RPMI is prepared at 0.4–0.5 × 106 cells/ml. Cells are mixed together with α-human IgM (final concentration of 5 μg/ml in each well) and vehicle (dimethyl sulfoxide) or AVL-292 (final concentrations of 0.01, 0.1, 1.0, 10.0, 100.0, or 1000 nM per well) and seeded in a 96-well plate. Cells are incubated for 56 hours in a humidified incubator maintained at 37°C and 5% CO2. 3H-Thymidine is added (final concentration of 1 μCi in each well) and cells are incubated overnight, harvested, and measured for 3H incorporation. Experiments are performed in triplicate.(Only for Reference) |
别名 | LMK-435, CC-292, AVL-292 |
分子量 | 423.44 |
分子式 | C22H22FN5O3 |
CAS No. | 1202757-89-8 |
Smiles | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 |
密度 | 1.322 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | Ethanol: < 1 mg/mL (insoluble or slightly soluble) DMSO: 79 mg/mL (186.6 mM) H2O: < 1 mg/mL (insoluble or slightly soluble) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容